Connect with trials tailored to your unique needs.
Take control of your health journey with confidence.
Support life-changing medical breakthroughs.
AI-powered technology for a smooth, transparent experience.
Ram Upadhayay is the Chief Executive Officer at Trial2Cure, where he directs the company's strategic vision and operations to drive innovation in healthcare. With a strong background in software development, artificial intelligence, and team leadership, Ram focuses on developing transformative solutions that enhance patient engagement and streamline clinical trial processes.
Prior to Trial2Cure, Ram was the founder and CEO of OXmaint, an AI-driven maintenance management platform, and co-founded Peearz Health, leveraging AI to improve healthcare outcomes. He has also held leadership roles at HVI.App and Infodat, managing software development and operational excellence.
Ram holds an MBA in Business Administration and Management from Madurai Kamaraj University and studied International Leadership at Harvard Business School.
Dr. Martin Schneider is the President and Chief Medical Officer at Trial2Cure, where he leads medical innovation and clinical strategy to advance patient care. With extensive experience in medical device development and clinical trials, he collaborates with experts to create cutting-edge healthcare solutions.
Previously, Dr. Schneider was a Postdoctoral Research Fellow at Stanford University School of Medicine, where he conducted pioneering research in photoacoustic imaging, earning the Vevo Research Award for his work on detecting vulnerable atherosclerotic plaque. He also mentored winning teams in Stanford's Biodesign programs, sharing his expertise in medical innovation and regulatory pathways.
Dr. Schneider holds an MD/PhD in Molecular Imaging from ETH Zurich and graduated magna cum laude with a Dr.med. in Medicine from the University of Tübingen.
Ajay Mohite is the Chief of Pharma Relations and Vice President of IT at Trial2Cure, where he leads pharmaceutical partnerships and oversees IT strategies to foster innovation in clinical trials. With over two decades of experience in the pharmaceutical and biotech industries, Ajay has a distinguished career in driving technology initiatives and aligning them with business goals.
Prior to joining Trial2Cure, Ajay held senior IT leadership roles at major companies like Intarcia Therapeutics, Gilead Sciences, Scios (a Johnson & Johnson company), Medivation (now part of Pfizer), Affymax, and Questcor Pharmaceuticals. He has led cross-functional teams in system integrations, data warehousing, and regulatory compliance with standards such as 21 CFR Part 11 and Sarbanes-Oxley.
Ajay holds a Master’s degree in Information Systems from the University of San Francisco. His expertise in business process re-engineering, project management, and strategic planning makes him a vital asset in advancing Trial2Cure’s mission to revolutionize patient care through technology.
Ashwin Kinikar is the Lead Software Engineer AI at Trial2Cure, where he is instrumental in developing innovative healthcare solutions through advanced AI integration. Specializing in full-stack development, Ashwin has significant expertise in Python, Java, JavaScript, and frameworks like Django, Spring Boot, ReactJS, and Node.js. He is passionate about incorporating cutting-edge AI technologies to enhance patient engagement and improve clinical trial processes.
Before joining Trial2Cure, Ashwin served as a Software Engineer at Amotions, Inc., where he built robust front-end solutions using TypeScript, Next.js, and React.js, and integrated AI tools with the OpenAI API. He also worked at Berkshire Hathaway, focusing on application development using Spring Boot and AWS.
Ashwin holds a Master’s degree in Computer Science from California State University - East Bay and a Bachelor’s degree in Computer Science from Pune University. He is committed to driving excellence in software development and leveraging AI/ML technologies to streamline healthcare operations.
Reach out to us from our contact form and we will get back to you shortly.